2023: First Rett Drug Approved

On This Day in Health: March 10, 2023

On March 10, 2023, the United States Food and Drug Administration approved trofinetide, marketed as Daybue, for adults and children aged two years and older with Rett syndrome. It was the first medicine specifically approved by the agency for this rare neurodevelopmental disorder. The decision followed years of laboratory investigation, clinical development, and participation by patients and families. It created a treatment option addressing aspects of the condition, while leaving the need for broader supportive care in place. The milestone was an important first authorization, rather than a cure or proof that the disorder's genetic cause had been removed.

Rett syndrome principally affects girls and is commonly associated with changes in the MECP2 gene. A period of apparently typical early development can be followed by loss of acquired skills, including purposeful hand use and communication. The condition can affect movement and other functions in ways that differ among individuals. Trofinetide's development grew partly from research on insulin-like growth factor 1 and how neural connections develop and adapt. Investigators explored whether a related therapeutic approach might offset some consequences of altered MECP2 function. Work in experimental models helped provide a rationale for moving toward clinical studies, but evidence from animals could not by itself establish a treatment's benefit for people.

The pivotal LAVENDER study compared trofinetide with placebo in 187 female participants aged five to twenty. Its main assessments included a caregiver questionnaire and a clinician's rating of improvement. These tools addressed changes in symptoms and functioning that were meaningful within the trial, rather than demonstrating a reversal of every effect of the disorder. The authorized age range also depended on a wider development program and evidence considered by the regulator. Diarrhea and vomiting were among the important adverse effects associated with treatment. The approval therefore combined a new opportunity with practical issues of tolerability, monitoring, and the continuing need to understand how the medicine could fit into each patient's care.

The path to March 10 shows how basic neuroscience can contribute to a clinical option over many years. Researchers studying developmental plasticity helped generate ideas that later required pharmaceutical development and human testing. Patients, caregivers, and investigators supplied the participation and observations needed to evaluate those ideas. An approval date is a visible marker for that collective process, but it does not describe the whole work or make research complete. For the Rett community, the first authorized medicine changed the available treatment landscape while leaving substantial needs unresolved. Its lasting significance is the movement of a research concept into a regulated therapy, with benefit and limitations assessed in people rather than inferred solely from a promising biological explanation.